CDY 1.43% 7.1¢ cellmid limited

Its not like you can go down to the store and ask for " a 6 pack...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,750 Posts.
    lightbulb Created with Sketch. 132
    Its not like you can go down to the store and ask for " a 6 pack of Midkine and a bucket of antibodies, please".
    There is a great jungle of clinical utility and regulation to hack through before even the scientists have sufficient information on all the various applications.

    Expecting the everyday "man in the street" to have the faintest idea of what Midkine entails might be a bit much. I know very little about it myself even after all these years.
    Try going up to someone outside of this forum and attempt to explain Midkine and watch the eyes glaze over in disinterest.
    Mention Evolis and what it is and they can immediately get a handle on it because it is a tangible product.

    Much better to focus on the Evolis in the meantime as this appears to be the key to getting the whole midkine program into the clinic and validated.

    Cashflow positive from Evolis sales appears to be not far away now if things keep improving the way they have and Fillerina may produce some waves or at least slosh some dosh down the spillway.

    That Chinese deal with Fukan Gren is quite interesting in that they have a year to obtain permits.
    Raises the question whether deliveries will start immediately the permits are obtained.
    It could only take 6 months or so with any kind of luck.

    Would be very interested in what those minimum annual supply figures are into a place the size of China.

    (Rust never sleeps)
 
watchlist Created with Sketch. Add CDY (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.